Kosh Agarwal, Maria Buti, Florian van Bömmel, Pietro Lampertico, Ewa Janczewska, Marc Bourliere, Thomas Vanwolleghem, Oliver Lenz, Thierry Verbinnen, Thomas N Kakuda, Cristiana Mayer, John Jezorwski, Daniel Muenz, Maria Beumont, Ronald Kalmeijer, Michael Biermer, Isabelle Lonjon-Domanec
BACKGROUND & AIMS: Functional cure (FC) for chronic hepatitis B (CHB) requires finite treatment. Two agents under investigation aimed at achieving FC are small interfering RNA JNJ-73763989 (JNJ-3989) and capsid assembly modulator JNJ-56136379 (JNJ-6379; bersacapavir). METHODS: REEF-2, a phase 2b, double-blind, placebo-controlled, randomized study (ClinicalTrials.gov Identifier: NCT04129554), enrolled 130 nucleos(t)ide analog (NA)-suppressed hepatitis B e-antigen (HBeAg)-negative CHB patients who received JNJ-3989 (200 mg subcutaneously every 4 weeks)+JNJ-6379 (250 mg oral daily)+NA (oral daily; active arm) or placebos for JNJ-3989 and JNJ-6379 + active NA (control arm) for 48 weeks followed by 48 weeks off-treatment follow-up...
April 5, 2024: Journal of Hepatology